FDA approves Merck’s Keytruda for lung cancer treatment

Keytruda, a lung cancer treatment medication manufactured by Merck was approved Oct. 24 by the U.S. Food and Drug Administration (FDA), reports The Wall Street Journal.

The medication, meant to treat patients with metastatic non-small cell lung cancer, can be used instead of chemotherapy for patients with this type of cancer.

Keytruda was initially approved in 2014 to treat melanoma and is in a clinical development program to determine if it can also treat 30 other tumor types.

To read more about the medication and how it will change how physicians treat lung cancer, follow the link below:

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

If passed, this bill would help clinician-led clinical registries explore Medicare data for research purposes. The Society of Thoracic Surgeons and American College of Cardiology both shared public support for the bipartisan legislation. 

Cardiologists and other physicians may soon need to provide much more information when ordering remote patient monitoring for Medicare patients.

Trimed Popup
Trimed Popup